Kura Oncology (NASDAQ:KURA) Given New $10.00 Price Target at Scotiabank

Kura Oncology (NASDAQ:KURA) had its target price decreased by Scotiabank from $18.00 to $10.00 in a report released on Wednesday morning,Benzinga reports. Scotiabank currently has a sector perform rating on the stock.

A number of other equities research analysts have also issued reports on the company. UBS Group initiated coverage on Kura Oncology in a research note on Thursday, October 24th. They set a “buy” rating and a $27.00 price target for the company. JMP Securities restated a “market outperform” rating and set a $32.00 target price on shares of Kura Oncology in a research note on Tuesday, November 19th. Lifesci Capital upgraded Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. StockNews.com cut Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, November 20th. Finally, Jefferies Financial Group lowered their price target on Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a research report on Thursday, November 21st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $27.38.

Kura Oncology Stock Performance

NASDAQ:KURA opened at $7.78 on Wednesday. The stock has a market capitalization of $605.00 million, a P/E ratio of -3.30 and a beta of 0.81. The stock has a 50-day moving average price of $12.11 and a 200 day moving average price of $17.08. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a 12-month low of $7.70 and a 12-month high of $24.17.

Institutional Investors Weigh In On Kura Oncology

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Suvretta Capital Management LLC increased its holdings in Kura Oncology by 8.2% in the 3rd quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company’s stock valued at $149,535,000 after purchasing an additional 583,155 shares in the last quarter. Sofinnova Investments Inc. lifted its holdings in Kura Oncology by 64.4% in the second quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock worth $16,992,000 after acquiring an additional 323,303 shares during the last quarter. Armistice Capital LLC lifted its holdings in Kura Oncology by 14.7% in the second quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock worth $48,386,000 after acquiring an additional 302,000 shares during the last quarter. Alethea Capital Management LLC increased its stake in shares of Kura Oncology by 108.2% in the third quarter. Alethea Capital Management LLC now owns 553,542 shares of the company’s stock valued at $10,816,000 after purchasing an additional 287,636 shares during the period. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Kura Oncology in the third quarter valued at approximately $3,695,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.